Novartis AG (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 163   

Articles published

NVS 85.84 -0.11 (-0.13%)
price chart
Is Selling Novartis AG (ADR) Here a Winning Strategy?
The stock of Novartis AG (ADR) (NYSE:NVS) hit a new 52-week low and has $79.83 target or 7.00% below today's $85.84 share price.
Trade of the Day: It's Not Too Late to Short NVS Stock
Novartis AG (ADR) (NVS) - I last featured NVS stock as the Trade of the Day on Oct. 1, recommending traders sell shares short at $95 with a downside target of $85.
How Analysts Rated Novartis AG (ADR) (NYSE:NVS) Last Week?
Notable Runners: Biogen Inc (NASDAQ:BIIB), Novartis AG (ADR) (NYSE:NVS ...
Novartis AG (ADR) (NYSE:NVS) lost -0.30% and closed the last trading session at $86.39. The market capitalization of the company is $238.26 billion with the total traded volume of the company is 1.62 million.
No One Is Above The Law; Novartis AG (ADR) Has To Pay
Novartis AG (ADR) (NYSE:NVS) has concluded a settlement with the U.S. Justice Department regarding the drugmaker's paid rebate to the specialty pharmacies and reached an agreement to make certain changes on interactions with them.
Novartis AG (ADR) Entresto Clinches EU approval
The Novartis (NYSE:NVS) drug Entresto has won approval from EU Regulators to treat chronic heart disease with a low ejection fraction.
Novartis Heart Failure Drug Entresto Approved By European Commission ...  The
Technical Report on Novartis AG (ADR) (NYSE:NVS)
[Zacks] Novartis AG (ADR) (NYSE:NVS)(TREND ANALYSIS) announced positive one-year results from a pivotal multi-center, randomized, placebo-controlled phase III study (FUTURE 2) on Cosentyx.
Novartis AG (ADR) (NYSE:NVS) Faces a Huge Fine as a Result of Allegations ...
Stock Report on Novartis AG (ADR) (NYSE:NVS)
[CNW Group] Novartis AG (ADR) (NYSE:NVS)(TREND ANALYSIS) announced one-year study results from the MEASURE 2 pivotal Phase III study of investigational secukinumab in ankylosing spondylitis (AS).
Here's Why Novartis AG (ADR) Fared Better Than Others
Novartis AG ADR (NYSE:NVS) has signed three deals to expand its reach in the immune-oncology market. On Wednesday, Novartis announced that it had acquired Admune Therapeutics, a cancer drug maker.
Novartis (NVS) Strengthens It's Pipeline With Admune Therapeutics & XOMA  CNA Finance (press release)
Novartis AG (ADR) to Decline On Q3 Earnings
The share price for Novartis AG ADR (NYSE:NVS) is expected to decline as the drug maker reported lower-than-expected sales and earnings for the third quarter of this fiscal (3QFY15).
Revenue Update on Novartis AG (NYSE:NVS)  News Watch International
Novartis (NVS) Misses on Q3 Earnings, Maintains 2015 View  Nasdaq
Novartis AG (ADR) (NVS) Earnings Per Share Expected to Increase
Analysts await Novartis AG (ADR) (NYSE:NVS) to reports earnings on October, 27. They expect $1.32 EPS, up 3.13% or $0.04 from last year's $1.28 per share.